Izervay vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Izervay | US Miebo | |
|---|---|---|
| Generic name | avacincaptad pegol | perfluorohexyloctane |
| Drug class | Complement C5 Inhibitor | Semifluorinated Alkane (Eye Drop) |
| Treats | Geographic atrophy (advanced dry AMD) | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Astellas Pharma | Bausch + Lomb |
| Year approved | 2023 | 2023 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Izervay or Miebo better?
Neither is universally "better." Izervay (avacincaptad pegol) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Izervay and Miebo?
Izervay is a Complement C5 Inhibitor made by Astellas Pharma, while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Izervay has the larger estimated TV advertising budget of the two.